G-CSF (Neupogen Roche) v lécbĕ pacientů s chronickou aplastickou anémií s tĕzkou neutropenií
[G-CSF (Neupogen Roche) in the treatment of patients with chronic aplastic anemia with severe neutropenia]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article
PubMed
8578701
- MeSH
- Anemia, Aplastic complications therapy MeSH
- Granulocyte Colony-Stimulating Factor therapeutic use MeSH
- Filgrastim MeSH
- Humans MeSH
- Neutropenia complications therapy MeSH
- Recombinant Proteins therapeutic use MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Names of Substances
- Granulocyte Colony-Stimulating Factor MeSH
- Filgrastim MeSH
- Recombinant Proteins MeSH
Aplastic anaemia (AA) of the chronic type with severe cytopenia is very frequently a difficult therapeutic problem. Patients with granulocyte values below 0.5 G/l are threatened by infections, incl. sepsis possibly with a fatal outcome. If the pool of stem cells for granulocytes is not completely exhausted and can respond to growth factors, these patients can be treated either chronically and/or in risk situations (e.g. injury, surgery) with preparations of the type of a recombinant, granulocyte colony stimulating factor (rhG-CSF), or granulocyte and monocyte colony stimulating factor (rhGM-CSF). The authors present a review of diagnostic and therapeutic algorithms in patients with the AA syndrome and summarize their own experience with the preparation Neupogen Roche (rhG-CSF).
